Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famitinib for unresectable progressive desmoid tumor
ChiCTR2500096838Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of famitinib in aggressive fibromatosis (AF), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Objective response rate. Started Jan 2025; status: recruiting.
02
Drugs
famitinib
03
Conditions
aggressive fibromatosis (AF)
Beyond the preview
Go deeper on ChiCTR2500096838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096838.